| An SI Board Since October 1996 |
| Posts |
SubjectMarks |
Bans |
Symbol |
| 120 |
2 |
0
|
BZET |
|
Biofield, BZET makes a breast cancer scanner that supposedly is much better than any other products currently on the market. The scanner is supposed to greatly enhance early detection, is non-invasive, and cost-effective.
European trials went very well, and BZET is going to present their US findings to the FDA within about 3 months.
The company has about $3 in cash + assets, so that is probably where the downside is limited to (still a large % change, however).
Hambrecht & Quist has either a "Strong Buy," or "Buy" recommendation on the company, I'll confirm which one tomorrow.
I don't mean to generate any hype, so I am trying to present both positive and negative FACTS about BZET. In my opinion, though, I think the stock should easily get to around $20 within the next three months, possibly four. That is what I have bet on (yes, I do own the stock). If the FDA presentation goes as expected (as I expect), I think the stock will easily meet my objective. Otherwise, the stock will go down.
The stock has a thin float, and is thinly traded, so it is more than capable of making large moves on any news (up or down). But due to these same factors, it could get subject to "Internet Hype." Please be careful.
Here is also short business summary taken from another web site:
Biofield Corp., a development stage company, has developed a system for detecting breast cancer through the skin in a non-invasive procedure. Biofield's system employs single-use sensors and a measurement device to detect and analyze changes in cellular electrical charge distributions. For the six months ended 6/30/96, the Company reported no revenue. Net loss increased 38% to $5M. Loss reflects costs associated with additional personnel.
|
